StockData
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc. (GLUE) stock

GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07−0.09 (-0.98%)

Close on Nov 17, 2026Market cap $773.79MP/E –Yield –

Earnings

Monte Rosa Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 16, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$54.40M
+325.0% on a year earlier
EPS, Q3 FY2026
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Monte Rosa Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 16, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026before the open$54.40M+325.0%–Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026before the open$9.00M-61.2%–Release
Q1 FY2026ended Mar 31, 2026May 7, 2026before the open$4.20M-95.1%–Release
Q4 FY2025ended Dec 31, 2025Mar 17, 2026before the open$2.80M-95.4%–Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025before the open$12.80M+39.1%–Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025before the open$23.20M+393.6%–Release
Q1 FY2025ended Mar 31, 2025May 8, 2025before the open$84.90M+7618.2%–Release
Q4 FY2024ended Dec 31, 2024Mar 20, 2025before the open$60.60M––Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024before the open$9.20M––Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024before the open$4.70M–-$0.43Release
Q1 FY2024ended Mar 31, 2024May 9, 2024before the open$1.10M–-$0.53Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Monte Rosa Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Monte Rosa Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Monte Rosa Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. Update
  5. Results
  6. Results
  7. Results
  8. News
  9. Update
  10. Update
  11. Update
  12. Update
  13. Results
  14. Update
  15. Results

See a number that looks wrong?